<DOC>
	<DOCNO>NCT01552434</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Avastin ( bevacizumab ) Torisel ( temsirolimus ) give combination either valproic acid cetuximab patient advance cancer refractory . The safety drug combination also study . Bevacizumab design block growth blood vessel , may help slow block growth cancer . Temsirolimus design block growth cancer cell , may cause cancer cell die . Valproic acid anti-seizure drug may able activate tumor-fighting gene , cause cancer cell die . Cetuximab design block certain protein , call EGFR , think cause cancer cell grow . This may cause cancer cell die .</brief_summary>
	<brief_title>Bevacizumab , Temsirolimus Alone Combination With Valproic Acid Cetuximab Patients With Advanced Malignancy Other Indications</brief_title>
	<detailed_description>Study Groups : If find eligible , assign study drug combination study doctor think best interest : - Drug Combination 1 : Temsirolimus , bevacizumab , cetuximab - Drug Combination 2 : Temsirolimus , bevacizumab , valproic acid - Drug Combination 3 : Temsirolimus bevacizumab Dose Escalation Group : You assign dose level study drug combination base join study . Up 11 dose level test Study Drug Combination 1 . Up 10 dose level test Study Drug Combinations 2 3 . Three ( 3 ) participant enrol dose level combination . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose study drug combination find . Dose Expansion Group : After high tolerable dose find , additional 10 participant , call `` dose expansion group , '' receive study drug combination dose . Ovarian Expansion Group : Up 14 additional participant ovarian cancer , call `` ovarian expansion group , '' receive Drug Combination 3 high tolerable dose . Study Drug Administration : The study drug give cycle . Cycles 28 day longer , depend side effect may . You give bevacizumab vein Days 1 15 cycle . On Day 1 Cycle 1 , receive 90 minute . If tolerate well Cycle 1 , receive 60 minute Cycle 2 . If tolerate well Cycle 2 , receive 30 minute Cycle 3 . As long still tolerate well , receive 30 minute Cycle 4 cycle . You give temsirolimus vein Days 1 , 8 , 15 , 22 cycle . During Day 1 Cycle 1 , receive 60 minute . If tolerate well Day 1 Cycle 1 , give 30 minute future dos , long continue tolerate well . If take Drug Combination 1 , give cetuximab vein 1 time every week . The first time receive cetuximab , give 2 hour . Every time receive cetuximab , give 1 hour . If take Drug Combination 2 , take valproic acid mouth 1 time day cycle . The drug take without food . Study Visits : One ( 1 ) time week Cycle 1 , follow test procedure perform : - You physical exam , include measurement weight vital sign . - Blood ( 1 tablespoon ) collect routine test . - Urine collect routine test first week Cycle 1 . Every 4 week Cycles 2 beyond : - You physical exam , include measurement weight vital sign . - Blood ( 1 tablespoon ) urine collect routine test . After Cycle 2 , CT MRI scan every 2 cycle check status disease . Ovarian Expansion Group : If ovarian expansion group additional testing follow : - You extra blood ( 2 teaspoon time ) drawn Cycle 1 . The blood use biomarker test . Biomarkers find blood/tissue may relate reaction study drug . This blood drawn : - Before begin take study drug - On Day 1 1 , 4 , 8 , 24 -36 hour start first infusion - On Day 6 , 7 , 8 - On Day 15 - At end Cycle 1 - You 2 core needle biopsy biomarker test screen visit end Cycle 1 . These sample use learn study drug combination act body learn effect cancer cell . To perform core needle biopsy , sample tissue remove use hollow core needle cut edge . - You dynamic contrast enhanced MRI ( DCE-MRI ) scan check status disease : - At screen - 24-48 hour start Cycle 1 - At end Cycle 1 Like regular MRI scan , DCE-MRI scan involves pass part body long , narrow tube scanner open end . Length Study : You may continue take study drug combination long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Bevacizumab FDA approve commercially available treatment colorectal cancer type lung cancer . Temsirolimus FDA approve commercially available treatment kidney cancer spread . Cetuximab FDA approve commercially available treatment colorectal cancer type head neck cancer . Valproic acid FDA approve commercially available help control seizures . The combination bevacizumab temsirolimus FDA approve treat advanced cancer . The combination bevacizumab temsirolimus cetuximab valproic acid FDA approve treat advanced cancer . At time , study drug combination use research . Up 216 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces complete response least 10 % improve survival least three month . In addition , patient diseases `` benign '' pathology , relentlessly progressive , leading disability , pain , premature death majority case ( include limit lymphangioleiomyomatosis ( LAM ) , type 2 neurofibromatosis ( NF ) , Erdheim Chester disease , Castleman 's disease ) may also consider enrollment 2 . Patients least four week last day therapeutic radiation cytotoxic chemotherapy antibody therapy , least five halflives noncytotoxic target biologic therapy . Patients may receive palliative radiation immediately ( ) treatment provide radiation target lesion available . 3 . ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 4 . Lansky performance status &gt; /= 60 % participant 16 year old young . 5 . Patients must allowable organ marrow function define : absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=50,000/mL ; creatinine &lt; /= 3 X ULN ; total bilirubin &lt; /= 3.0 ; AST ( SGOT ) /ALT ( SGPT ) &lt; /= 5 X ULN ; fast level total cholesterol 350mg/dL ; triglyceride level 400mg/dL . 6 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day last dose . 7 . Ability understand willingness sign write informed consent document . 8 . Patients may receive investigational agent and/or concurrent anticancer agent therapy . 1 . Patients clinically significant unexplained bleeding within 28 day prior enter study . 2 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg medication ) . 3 . Patients clinically significant cardiovascular disease : History CVA ( cerebrovascular accident ) within 6 month , Myocardial infarction unstable angina within 6 month , Unstable angina pectoris 4 . Pregnant breastfeed woman . 5 . History hypersensitivity bevacizumab , murine product , component formulation . 6 . History hypersensitivity Temsirolimus metabolite ( include sirolimus ) , polysorbate 80 , component formulation . 7 . History hypersensitivity cetuximab , murine product , component formulation . 8 . Patients take CYP3A4 inducer and/or inhibitor . Please see section `` Drug Information '' detail . If patient history take CYP3A4 inducer and/or inhibitor prior enrollment protocol , strongly recommend patient stop drug wait least 5 halflives say drug initiate therapy protocol . 9 . Colorectal cancer patient know KRAS mutation ( arm combining bevacizumab , temsirolimus cetuximab ) 10 . Patients major surgery within 6 week enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Advanced Malignancy</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Torisel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Anti-VEGF Monoclonal Antibody</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>C225</keyword>
	<keyword>Erbitux</keyword>
	<keyword>IMC-C225</keyword>
	<keyword>Valproic Acid</keyword>
	<keyword>Depakene</keyword>
</DOC>